This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

TCS Named As A Leader In Life Science Drug Safety Services By Leading Industry Research Firm





MUMBAI, India, Feb. 28, 2013 /PRNewswire/ -- Tata Consultancy Services (TCS), (BSE: 532540, NSE: TCS) a leading IT services, consulting and business solutions organization, announced that it has been designated as a Leader in Life Science Drug Safety Services (DSS) by the prominent global market intelligence firm IDC. Among the attributes that earned TCS its leadership position in the " IDC MarketScape: Worldwide Life Science Drug Safety Services 2013 Vendor Assessment" (Document # HI239221) are the company's significant industry expertise, strong drug safety IT and KPO delivery capabilities and investment in drug safety specific IP assets.

IDC MarketScape reports are designed to identify factors conducive to success in a particular market, both long term and short term, and then assess vendors participating in the market against these factors. The criteria for each IDC MarketScape report is developed by IDC analysts and can include discussions, surveys and interviews. For this report, the key criteria for defining excellence included: breadth of service offerings, diversity of resources and infrastructure-supporting services delivery, project experience in the Life Sciences DSS outsourcing market, customer service strategy and customer satisfaction, pricing model, go-to-market capabilities and commitment to growth and innovation in the R&D DSS space.

"TCS' large Life Science customer base, broad industry-centric services portfolio, competitive pricing, and strong commitment to growth ensure that the company will continue to be a leading service provider to the industry over both the near and long term," said the report's author, Alan S. Louie, Ph.D., Research Director, Clinical Development Strategy and Technology, IDC Health Insights.

"For TCS and our Life Sciences customers, patient safety is the absolute priority and we are honored to be listed as a Leader by IDC Health Insights in the Drug Safety market," said Debashis Ghosh, President, Life Sciences, Manufacturing and Energy at TCS. "This recognition is a testament to our commitment to our customers, of constantly innovating and delivering superior drug safety services, and helping companies in ensuring enhanced care for their patients."

"To be named as a Leader in the Drug Safety Market by IDC Health Insights is indeed a recognition of our differentiated strategy of providing core business services by investing in deep domain expertise and regulatory knowledge. TCS' market leading capabilities in the drug safety space, including adverse event tracking and aggregate reporting, help the pharmaceutical industry meet their compliance requirements more effectively," said Abid Ali Neemuchwala, Global Head, TCS BPO Services.

TCS' drug safety services help customers enhance efficiency, reduce costs significantly and ensure regulatory compliance. TCS' customers benefit from the company's domain knowledge, global reach, quality systems approach, multi-disciplinary safety expertise and adherence to reporting timelines of the EMEA, FDA, MHRA and other industry authorities.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,461.32 -153.49 -0.92%
S&P 500 1,927.11 -14.17 -0.73%
NASDAQ 4,382.8470 -36.6310 -0.83%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs